Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jaclyn Flanigan, Hari Deshpande, Scott Gettinger
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/cf568a52e46640e89d9b6362ec98daa2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf568a52e46640e89d9b6362ec98daa2
record_format	dspace
spelling	oai:doaj.org-article:cf568a52e46640e89d9b6362ec98daa22021-12-02T03:11:29ZCurrent status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer1177-54751177-5491https://doaj.org/article/cf568a52e46640e89d9b6362ec98daa22010-08-01T00:00:00Zhttp://www.dovepress.com/current-status-of-vandetanib-zd6474-in-the-treatment-of-non-small-cell-a5138https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged as instrumental in the growth and metastasis of multiple malignancies, including non-small cell lung cancer (NSCLC). Indeed, inhibitors of each pathway have been approved by the US Food and Drug Administration for use in advanced NSCLC. As there is considerable cross talk between these pathways, dual inhibition with such agents has become an attractive strategy, with encouraging Phase II clinical trial data to date. The convenience of one oral agent targeting both pathways is clear, and clinical trials have established the maximum tolerated daily dose of vandetanib, with data from randomized Phase III trials emerging. This report will review completed and ongoing NSCLC clinical trials evaluating vandetanib, and speculate on the future of this agent in NSCLC.Keywords: Zactima, ZD6474, non-small cell lung cancer, vandetanib Jaclyn FlaniganHari DeshpandeScott GettingerDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 237-243 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jaclyn Flanigan Hari Deshpande Scott Gettinger Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
description	Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged as instrumental in the growth and metastasis of multiple malignancies, including non-small cell lung cancer (NSCLC). Indeed, inhibitors of each pathway have been approved by the US Food and Drug Administration for use in advanced NSCLC. As there is considerable cross talk between these pathways, dual inhibition with such agents has become an attractive strategy, with encouraging Phase II clinical trial data to date. The convenience of one oral agent targeting both pathways is clear, and clinical trials have established the maximum tolerated daily dose of vandetanib, with data from randomized Phase III trials emerging. This report will review completed and ongoing NSCLC clinical trials evaluating vandetanib, and speculate on the future of this agent in NSCLC.Keywords: Zactima, ZD6474, non-small cell lung cancer, vandetanib
format	article
author	Jaclyn Flanigan Hari Deshpande Scott Gettinger
author_facet	Jaclyn Flanigan Hari Deshpande Scott Gettinger
author_sort	Jaclyn Flanigan
title	Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
title_short	Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
title_full	Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
title_fullStr	Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
title_full_unstemmed	Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
title_sort	current status of vandetanib (zd6474) in the treatment of non-small cell lung cancer
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/cf568a52e46640e89d9b6362ec98daa2
work_keys_str_mv	AT jaclynflanigan currentstatusofvandetanibzd6474inthetreatmentofnonsmallcelllungcancer AT harideshpande currentstatusofvandetanibzd6474inthetreatmentofnonsmallcelllungcancer AT scottgettinger currentstatusofvandetanibzd6474inthetreatmentofnonsmallcelllungcancer
_version_	1718401946552893440

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

Ejemplares similares